114 related articles for article (PubMed ID: 24002513)
1. Reply to Z. Blumenfeld et al.
Demeestere I; Brice P; Peccatori FA; Kentos A; Gaillard I; Zachee P; Casasnovas O; Van Den Neste E; Dechene J; De Maertelaer V; Bron D; Englert Y
J Clin Oncol; 2013 Oct; 31(29):3722-3. PubMed ID: 24002513
[No Abstract] [Full Text] [Related]
2. GnRH agonist for the prevention of chemotherapy-induced ovarian failure in lymphoma.
Blumenfeld Z; Dann E
J Clin Oncol; 2013 Oct; 31(29):3721. PubMed ID: 24002509
[No Abstract] [Full Text] [Related]
3. Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial.
Demeestere I; Brice P; Peccatori FA; Kentos A; Gaillard I; Zachee P; Casasnovas RO; Van Den Neste E; Dechene J; De Maertelaer V; Bron D; Englert Y
J Clin Oncol; 2013 Mar; 31(7):903-9. PubMed ID: 23129737
[TBL] [Abstract][Full Text] [Related]
4. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.
Del Mastro L; Boni L; Michelotti A; Gamucci T; Olmeo N; Gori S; Giordano M; Garrone O; Pronzato P; Bighin C; Levaggi A; Giraudi S; Cresti N; Magnolfi E; Scotto T; Vecchio C; Venturini M
JAMA; 2011 Jul; 306(3):269-76. PubMed ID: 21771987
[TBL] [Abstract][Full Text] [Related]
5. Gonadotropin-releasing hormone for preservation of ovarian function during chemotherapy in lymphoma patients of reproductive age: a summary based on 434 patients.
Zhang Y; Xiao Z; Wang Y; Luo S; Li X; Li S
PLoS One; 2013; 8(11):e80444. PubMed ID: 24312222
[TBL] [Abstract][Full Text] [Related]
6. Trying to reduce ovarian damage in patients with Hodgkin lymphoma using GnRH agonists?
Oktay K; Sonmezer M; Barad D; Gleicher N
Fertil Steril; 2009 Jan; 91(1):298-9; author reply 299. PubMed ID: 19046580
[No Abstract] [Full Text] [Related]
7. Comment on the symposium article "Fertility after treatment for Hodgkin's disease", by Z. Blumenfeld, E. Dann, I. Avivi et al. (Ann Oncol 2002; 13 Suppl 1: 138-147).
Bohlmann MK; von Wolff M; Strowitzki T
Ann Oncol; 2003 Mar; 14(3):499; author reply 499-500. PubMed ID: 12598361
[No Abstract] [Full Text] [Related]
8. Gonadotropin-releasing hormone analogue for premenopausal women with breast cancer.
Loibl S; Gerber B
JAMA; 2011 Oct; 306(16):1760; author reply 1760-1. PubMed ID: 22028347
[No Abstract] [Full Text] [Related]
9. Reducing the long-term effects of chemotherapy in young women with early-stage breast cancer.
Rugo HS; Rosen MP
JAMA; 2011 Jul; 306(3):312-4. PubMed ID: 21771995
[No Abstract] [Full Text] [Related]
10. Gonadotropin-releasing hormone agonists for the preservation of ovarian function during chemotherapy.
Tomao F; Benedetti Panici P; Tomao S
J Clin Oncol; 2012 Sep; 30(26):3310-1; author reply 3312-3. PubMed ID: 22649128
[No Abstract] [Full Text] [Related]
11. Triptorelin for Fertility Preservation in Adolescents Treated With Chemotherapy for Cancer.
Meli M; Caruso-Nicoletti M; La Spina M; Nigro LL; Samperi P; D'Amico S; Bellia F; Miraglia V; Licciardello M; Cannata E; Marino S; Cimino C; Puglisi F; Valvo LL; Pezzulla A; Russo G; Di Cataldo A
J Pediatr Hematol Oncol; 2018 May; 40(4):269-276. PubMed ID: 29620680
[TBL] [Abstract][Full Text] [Related]
12. No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial.
Demeestere I; Brice P; Peccatori FA; Kentos A; Dupuis J; Zachee P; Casasnovas O; Van Den Neste E; Dechene J; De Maertelaer V; Bron D; Englert Y
J Clin Oncol; 2016 Aug; 34(22):2568-74. PubMed ID: 27217453
[TBL] [Abstract][Full Text] [Related]
13. Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD).
Giuseppe L; Attilio G; Edoardo DN; Loredana G; Cristina L; Vincenzo L
Hematology; 2007 Apr; 12(2):141-7. PubMed ID: 17454195
[TBL] [Abstract][Full Text] [Related]
14. Gonadotropin-releasing hormone agonist for preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.
Blumenfeld Z
J Clin Oncol; 2012 Sep; 30(26):3310; author reply 3312-3. PubMed ID: 22649145
[No Abstract] [Full Text] [Related]
15. Successful co-treatment with LHRH-agonist for ovarian over-stimulation and cystic formation in premenopausal tamoxifen exposure.
Cohen I; Tepper R; Figer A; Flex D; Shapira J; Beyth Y
Breast Cancer Res Treat; 1999 May; 55(2):119-25. PubMed ID: 10481939
[TBL] [Abstract][Full Text] [Related]
16. Unintended pregnancy after gonadal failure chemoprevention with gonadotropin-releasing hormone agonist in women with hematologic malignancies.
Castelo-Branco C; Rabanal A; Nomdedeu B; Durán M; Arigita M; Balasch J
Fertil Steril; 2009 Oct; 92(4):1260-1263. PubMed ID: 19732883
[TBL] [Abstract][Full Text] [Related]
17. Gonadotropin-releasing hormone analog treatment for the prevention of treatment-related ovarian failure and infertility in women of reproductive age with Hodgkin lymphoma.
Falorio S; Angrilli F; Fioritoni G
Leuk Lymphoma; 2008 Jun; 49(6):1087-93. PubMed ID: 18452079
[TBL] [Abstract][Full Text] [Related]
18. Potential late effect of gonadotropin-releasing hormone agonists in combination with chemotherapy for early breast cancer.
Saloustros E; Stratakis CA
J Clin Oncol; 2012 Sep; 30(26):3311-2. PubMed ID: 22649148
[No Abstract] [Full Text] [Related]
19. Questioning GnRH analogs for gonadal protection in cancer patients.
Oktay K; Sönmezer M
Fertil Steril; 2009 Aug; 92(2):e32; author reply e34. PubMed ID: 19646599
[No Abstract] [Full Text] [Related]
20. A pilot study to assess the use of the gonadotrophin antagonist cetrorelix in preserving ovarian function during chemotherapy.
Whitehead J; Toledo MG; Stern CJ
Aust N Z J Obstet Gynaecol; 2011 Oct; 51(5):452-4. PubMed ID: 21810087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
